NVO Stock Today: February 4 — Guides 2026 Sales/Profit Down 5–13%, Shares Sink

Novo Nordisk stock fell sharply today after management guided 2026 sales and operating profit down 5-13%, citing US pricing pressure and loss of exclusivity for semaglutide in China, Brazil and Canada. The US ADS, NVO, traded at $50.30, down 14.6% intraday. UK investors are weighing near-term margin pressure against potential upside from a US oral Wegovy launch and higher-dose rollouts in 2026. The company reports today at 13:30 GMT, and management commentary on pricing, capacity and payor access will be critical.

What drove today’s drop and the 2026 reset

Management signalled a 5-13% decline in 2026 sales and operating profit. The reset reflects tougher US pricing, especially as payors push for higher rebates in obesity and diabetes. It also reflects loss of exclusivity for semaglutide across key ex-US markets. These factors compress gross-to-net and margins. The stock reaction highlights how consensus had not fully priced tighter US net pricing and regional LOE timing.

The ADS traded at $50.30, down 14.6%, with volume of 69.2 million versus a 23.1 million average. Day range was $49.96-$58.64. The 50-day average is $53.22 and the 200-day is $58.84. One-year performance is -39.1% versus a 52-week high of $93.80 and low of $43.08. RSI sits at 75.8, indicating overbought conditions into elevated volatility.

Management emphasised competition and pricing pressure alongside opportunities from oral formulations and higher-dose launches. Investors should watch commentary on capacity additions, access wins and the cadence of international launches. News reports flagged mounting competition in obesity care and the risk of slower net price realisation in the United States. See reporting from the Financial Times and CNBC for detail.

Implications for UK investors

Most UK investors hold the ADS listed in New York, so pricing is in US dollars. FX can add noise to returns in GBP. Consider whether to hedge currency exposure if holding the name in ISAs or SIPPs. Position sizing matters given single-stock volatility and sector concentration within healthcare.

While NHS reimbursement dynamics differ from US commercial plans, demand signals from UK obesity care are strong. However, the near-term share move is mainly about US net pricing and ex-US semaglutide LOE. For UK holders, monitor European pricing discussions, capacity expansion into the region and any updates on supply prioritisation that could affect availability.

The company is set to report at 13:30 GMT today. The trailing dividend yield is about 2.45% with a payout ratio near 49.9%. Income investors should assess dividend safety against lower operating profit guidance and a current ratio below 0.78, which implies tighter near-term liquidity compared with some large-cap peers.

Competition, Wegovy outlook and payor access

Competitive pressure from Eli Lilly’s obesity franchise is intensifying, raising the bar on efficacy, tolerability and supply. This rivalry accelerates innovation but also weighs on pricing. Expect more payor step edits, prior authorisations and tighter formulary tiers as plans balance outcomes with budget impact in both diabetes and obesity segments.

The Wegovy sales outlook hinges on access, adherence and dose availability. An oral formulation could widen the addressable base by reducing injection barriers. Success depends on cardiovascular outcomes data, manufacturing throughput and competitive rebate strategies. If adoption skews to orals, margin mix could change, so investors should watch gross-to-net disclosures next quarter.

US list-to-net pressure remains the key swing factor for 2026. Outside the US, semaglutide loss of exclusivity in China, Brazil and Canada will open the door to lower-cost rivals. That could compress international revenue even if volume holds. Management’s contracting strategy and lifecycle extensions will be central to stabilising ex-US markets.

Valuation, technicals and scenarios to track

On today’s move, the PE is about 13.6, with an EV to EBITDA near 9.1 and dividend yield around 2.45%. Profitability metrics remain strong, including a 33% net margin and return on equity near 67%. The balance sheet shows debt to equity of about 0.60, which is manageable but requires careful capital allocation in a lower-growth year.

Price sits below the 200-day average of $58.84 and near the Bollinger middle band at $51.90, signalling possible consolidation. ATR at 1.79 points to elevated day-to-day swings. Watch for sustained closes back above the 50-day at $53.22 or breaks below $49.96 to gauge momentum. Volume spikes suggest capitulation risk but also potential for sharp rebounds.

Bull case: successful US oral launch, improved supply, and better-than-feared net pricing drive mid-year stabilisation. Bear case: faster LOE erosion ex-US and tougher rebates cap growth. Key catalysts include capacity updates, payor contracts, dose availability and any guidance revisions. External coverage provides helpful context on risks and competition source and source.

Final Thoughts

Novo Nordisk stock is resetting as management guides 2026 sales and operating profit down 5-13% on US pricing pressure and looming semaglutide loss of exclusivity in key markets. The reaction reflects lower net price expectations and a more competitive obesity landscape with Eli Lilly. For UK investors, the next checkpoints are management’s commentary on pricing, payor access, dose availability and capacity. We would track whether oral obesity treatments can expand the market in 2026, and how rebates evolve across channels. Technically, watch the 50-day and 200-day moving averages for trend confirmation, and respect higher volatility. If you hold, review position size and risk limits. If you are researching an entry, consider scaling, waiting for clarity on access wins, and aligning exposure with your time horizon and currency view.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.